Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

Recalls, Market Withdrawals, & Safety Alerts > Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

Recalls, Market Withdrawals, & Safety Alerts > Sun Pharmaceutical Industries Inc. Issues Voluntary Nationwide Recall of Riomet® (Metformin Hydrochloride Oral Solution) Manufactured by a Contract Manufacturer due to Microbial Contamination

AstraZeneca Pharma India and Sun Pharmaceutical Industries today said they have entered into a distribution services agreement for AstraZeneca’s brand Axcer, a new brand of ticagrelor, in India. - See more at: http://ways2capital-equitytips.blogspot.in/2015/06/sun-pharma-astrazeneca-in-distribution.html#sthash.Wg2ewbNP.dpuf

AstraZeneca Pharma India and Sun Pharmaceutical Industries today said they have entered into a distribution services agreement for AstraZeneca’s brand Axcer, a new brand of ticagrelor, in India.

Sun Pharmaceutical Industries Ltd has informed BSE that one of the Company's wholly-owned subsidiaries has voluntarily

Sun Pharmaceutical Industries (Sun Pharma) has received the order passed by National Company Law Tribunal (NCLT) at Ahmedabad bench in the matter of Scheme

Sun Pharmaceutical Industries Ltd announced today the successful completion of its acquisition of InSite Vision Incorporated.

Shares of Sun Pharma were lower by at company posted a net profit after taxes, Minority Interest and Share of Profit/(Loss) of Associates of Rs. mn for the quarter ended September 2015

Shares of Sun Pharmaceutical Industries gained more than 1 percent Tuesday on completion of acquisition of Opiates business in Australia. - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharma-up-1-completes-acquisition.html#sthash.ns0cKyxJ.dpuf

Drug major Sun Pharmaceutical Industries on Wednesday said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules.

Sun Pharmaceutical Industries Ltd has announced the following consolidated results for the quarter ended June 30, 2016:

Sun Pharma ended lower at on BSE. The pharma company received a Warning Letter from the US FDA as a result of the September 2014 inspection, for its facility located at Halol, Gujarat in India.

Shares of Sun Pharmaceutical Industries gained 2.8 percent intraday Tuesday. On an annualised basis, - See more at: http://ways2capital.blogspot.in/2015/06/sun-pharma-up-3-raises-ranbaxys.html#sthash.UYkRxhLn.dpuf

Sun Pharma Advanced Research Co. Ltd (SPARC) has filed draft papers with the Securities and Exchange Board of India (Sebi) to raise up to Rs.

Drug major Sun Pharmaceutical Industries on Wednesday said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules. - See more at: http://ways2capital-review.blogspot.in/2015/08/sun-pharma-gets-usfda-approval-for-acne.html#sthash.OBisNDqH.dpuf

Drug major Sun Pharmaceutical Industries on Wednesday said it has received approval from the US health regulator for its new drug application for acne treatment medicine--XiminoTM extended-release capsules.

Sun Pharmaceuticals Industries Ltd is currently trading at Rs. 849, up by 8.6 points or 1.02% from its previous closing of Rs. 839.7 - See more at: http://ways2capital-equitytips.blogspot.in/2015/09/sun-pharmaceutical-may-divest.html#sthash.CPXETRiL.dpuf

Shares of Sun Pharmaceutical Industries, India’s largest drug maker, are currently trading lower at Rs. on BSE. The company has singed a global deal with ICGEB for treatment of Dengue.

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets 100mg and 400mg Imatinib Mesylate tablets,

Sun Pharmaceutical Industries Ltd announced that one of its subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Gleevec , Imatinib Mesylate tablets and Imatinib Mesylate tablets,

10 inspiring business quotes from the top 10 richest people in Asia! \m/ Rank 9 Net worth: $16.4 billion Age: 60 Country: India Industry: Pharmaceuticals Source of wealth: Self-made; Sun Pharmaceutical Industries  #Business #inspiration #motivation #life #quotes #asia #contactdb #databaseprovider #2of10

10 inspiring business quotes from the top 10 richest people in Asia! \m/ Rank 9 Net worth: $16.4 billion Age: 60 Country: India Industry: Pharmaceuticals Source of wealth: Self-made; Sun Pharmaceutical Industries #Business #inspiration #motivation #life #quotes #asia #contactdb #databaseprovider #2of10

Sun Pharmaceutical Industries Ltd. has recalled 68,000 bottles of the antidepressant Effexor in the U.S., in the second recall of the drug this year, the U.S. Food and Drug Administration said http://online.wsj.com/articles/sun-pharma-recalls-effexor-in-u-s-1416297616?mod=WSJ_LatestHeadlines

Sun Pharma Recalls Effexor in U.S.

A man carrying a gas cylinder walks out of the research and development centre of Sun Pharmaceutical Industries in Mumbai.

Drug major Sun Pharmaceutical Industries has said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a whol...

Sun Pharma raises Rs 1,000 cr via NCDs

Drug major Sun Pharmaceutical Industries has said it has raised Rs 1,000 crore through issuance of non-convertible debentures (NCDs) on private placement basis. "Sun Pharma Laboratories Ltd, a whol...

Pinterest
Search